This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/mixture/
n24http://www.rxlist.com/
n17http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n4http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB06692/identifier/national-drug-code-directory/
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06692
rdf:type
n5:Drug
n5:description
Aprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; after this was confirmed by follow-up studies, Trasylol was entirely and permanently withdrawn in May 2008, except - at least for the time being - for very restricted research use. [Wikipedia]
n5:generalReferences
# Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15277296
n5:group
withdrawn approved
n5:halfLife
Following this distribution phase, a plasma half-life of about 150 minutes is observed. At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.
n5:indication
For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
owl:sameAs
n17:DB06692 n19:DB06692
dcterms:title
Aprotinin
adms:identifier
n7:PA448472 n8:0026-8196-36 n12:Aprotinin n13:D02971 n21:DB06692
n5:mechanismOfAction
Aprotinin inhibits several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml. Its action on kallikrein leads to the inhibition of the formation of factor XIIa. As a result, both the intrinsic pathway of coagulation and fibrinolysis are inhibited. Its action on plasmin independently slows fibrinolysis.
n5:packager
n22:271B4E6F-363D-11E5-9242-09173F13E4C5 n22:271B4E6E-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Following a single IV dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours. After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug. After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.
n5:synonym
BPTI bovine pancreatic trypsin inhibitor Trazinin Iniprol
n14:hasAHFSCode
n23:20-28-16
n5:mixture
n18:271B4E6B-363D-11E5-9242-09173F13E4C5 n18:271B4E6C-363D-11E5-9242-09173F13E4C5 n18:271B4E6D-363D-11E5-9242-09173F13E4C5
n5:synthesisReference
Marion Steinbuch, Jacques Chabbat, Olivier Taby, "Process for preparation of activated protein C by immobilized aprotinin chromatography." U.S. Patent US5198534, issued February, 1985.
n10:hasConcept
n11:M0011905
foaf:page
n4:aprotinin.html n24:trasylol-drug.htm
n5:Molecular-Formula
n9:271B4E72-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n9:271B4E71-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:B02AB01
n5:absorption
100% (IV)
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
9087-70-1
n5:category
n5:Melting-Point
n9:271B4E70-363D-11E5-9242-09173F13E4C5